Akademik Veri Yönetim Sistemi
Serdar M. A. , Sertoglu E., Uyanik M., Tapan S., Akin O., Cihan M.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.68, ss.525-529, 2011 (SCI İndekslerine Giren Dergi)
Purpose 5-Fluorouracil (5-FU), acting as a pyrimidine antagonist, is a major chemotherapy drug used for the treatment of tumors such as gastrointestinal, breast, ovary, and head and neck cancers. The key and rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase (DHPDH), whose partial or complete deficiency exposes to a severe 5-FU toxicity in patients. The determination of DHPDH activity in patients before the treatment and setting up a personalized therapy for each patient receiving the drug can help us to prevent the possible risk of toxicity.